FR2380782A1 - Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer - Google Patents
Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparerInfo
- Publication number
- FR2380782A1 FR2380782A1 FR7804718A FR7804718A FR2380782A1 FR 2380782 A1 FR2380782 A1 FR 2380782A1 FR 7804718 A FR7804718 A FR 7804718A FR 7804718 A FR7804718 A FR 7804718A FR 2380782 A1 FR2380782 A1 FR 2380782A1
- Authority
- FR
- France
- Prior art keywords
- thymosin
- fraction
- useful
- stabilized
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une forme solide stable de fraction 5 de thymosine exempte d'endotoxines et de pyrogènes. Cette forme de fraction 5 de thymosine est préparée par un procédé comprenant en combinaison : a. L'ultrafiltration d'une solution aqueuse de fraction 5 de thymosine tamponnée avec un tampon basique faiblement volatil à un pH de 7 à 8 à travers une membrane ayant un seuil de coupure correspondant à une masse moléculaire de 10 000 environ; b. L'addition d'un agent antimicrobien de type phénolique au produit de perméation et d'un agent de tamponnage en quantité suffisante pour fournir un pH de 7-8 lors de la reconstitution, et c. La lyophilisation du produit de perméation, l'agent antimicrobien du type phénolique étant retenu avec la fraction 5 de thymosine lyophilisée. Cette forme stable est utile à la préparation de solution pour injection.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/770,480 US4082737A (en) | 1977-02-22 | 1977-02-22 | Stabilized thymosin composition and method |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2380782A1 true FR2380782A1 (fr) | 1978-09-15 |
FR2380782B1 FR2380782B1 (fr) | 1980-01-18 |
Family
ID=25088687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR7804718A Granted FR2380782A1 (fr) | 1977-02-22 | 1978-02-20 | Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer |
Country Status (20)
Country | Link |
---|---|
US (1) | US4082737A (fr) |
JP (1) | JPS53104719A (fr) |
AT (1) | AT363177B (fr) |
AU (1) | AU516946B2 (fr) |
BE (1) | BE864139A (fr) |
CA (1) | CA1099633A (fr) |
CH (1) | CH632164A5 (fr) |
DE (1) | DE2807202C2 (fr) |
DK (1) | DK78378A (fr) |
FR (1) | FR2380782A1 (fr) |
GB (1) | GB1546027A (fr) |
IE (1) | IE46409B1 (fr) |
IL (1) | IL54063A0 (fr) |
IT (1) | IT1092337B (fr) |
LU (1) | LU79090A1 (fr) |
NL (1) | NL189281C (fr) |
NZ (1) | NZ186489A (fr) |
PH (1) | PH13858A (fr) |
SE (1) | SE444647B (fr) |
ZA (1) | ZA78890B (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2732587A1 (de) * | 1976-09-22 | 1978-03-23 | Bach Jean Francois | Polypeptid mit thymischer wirksamkeit |
US4148788A (en) * | 1978-01-23 | 1979-04-10 | Hoffmann-La Roche Inc. | Synthesis of thymosin α1 |
US4239498A (en) * | 1978-11-27 | 1980-12-16 | Rule Allyn H | Method of preparing thymic factors and composition |
US4264571A (en) * | 1979-01-22 | 1981-04-28 | George Washington University | Radioimmunoassay of thymosin α1 |
EP0057702A1 (fr) * | 1980-08-08 | 1982-08-18 | Rak-A-Van Pty Limited | Systeme d'etageres ameliore |
US4389343A (en) * | 1981-12-24 | 1983-06-21 | Hoffmann-La Roche Inc. | Immunopotentiating peptides from thymus |
US4388234A (en) * | 1981-12-28 | 1983-06-14 | Hoffmann-La Roche Inc. | Peptide isolation |
US4614731A (en) * | 1983-09-15 | 1986-09-30 | Hoffmann-La Roche Inc. | Peptide having immunopotentiating activity similar to thymosin alpha1 |
US4659694A (en) * | 1983-10-27 | 1987-04-21 | Hoffmann-La Roche Inc. | Prothymosin alpha |
US4814434A (en) * | 1984-02-03 | 1989-03-21 | Ventres Laboratories, Inc. | Inducer of T-suppressor cells |
DE3633651A1 (de) * | 1986-10-03 | 1988-04-14 | Alfred Dr Dick | Verwendung von fraktionen aus thymus- und milzextrakten zur behandlung der psoriasis |
US5273963A (en) * | 1991-03-29 | 1993-12-28 | The George Washington University | Compositions and methods for treating small cell and nonsmall cell lung cancers |
JP4404866B2 (ja) | 2006-03-03 | 2010-01-27 | ゼライス株式会社 | エンドトキシン含有量を低減したゼラチンの製造方法および低エンドトキシンゼラチン |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4002602A (en) * | 1974-03-11 | 1977-01-11 | Gideon Goldstein | Ubiquitous immunopoietic polypeptide (UBIP) and methods |
US4010148A (en) * | 1975-05-12 | 1977-03-01 | Board Of Regents Of The University Of Texas System | Purified thymosin and process |
US4002740A (en) * | 1975-08-21 | 1977-01-11 | Gideon Goldstein | Tridecapeptide compositions and methods |
-
1977
- 1977-02-22 US US05/770,480 patent/US4082737A/en not_active Expired - Lifetime
-
1978
- 1978-01-18 CH CH51178A patent/CH632164A5/de not_active IP Right Cessation
- 1978-01-30 IT IT19791/78A patent/IT1092337B/it active
- 1978-02-06 CA CA296,326A patent/CA1099633A/fr not_active Expired
- 1978-02-07 NL NLAANVRAGE7801422,A patent/NL189281C/xx not_active IP Right Cessation
- 1978-02-15 ZA ZA00780890A patent/ZA78890B/xx unknown
- 1978-02-15 NZ NZ186489A patent/NZ186489A/xx unknown
- 1978-02-16 AU AU33343/78A patent/AU516946B2/en not_active Expired
- 1978-02-16 IL IL54063A patent/IL54063A0/xx not_active IP Right Cessation
- 1978-02-16 IE IE335/78A patent/IE46409B1/en not_active IP Right Cessation
- 1978-02-20 FR FR7804718A patent/FR2380782A1/fr active Granted
- 1978-02-20 LU LU79090A patent/LU79090A1/fr unknown
- 1978-02-20 JP JP1774678A patent/JPS53104719A/ja active Granted
- 1978-02-20 DE DE2807202A patent/DE2807202C2/de not_active Expired
- 1978-02-21 GB GB6845/78A patent/GB1546027A/en not_active Expired
- 1978-02-21 DK DK78378A patent/DK78378A/da unknown
- 1978-02-21 AT AT0124578A patent/AT363177B/de not_active IP Right Cessation
- 1978-02-21 SE SE7802014A patent/SE444647B/sv unknown
- 1978-02-21 PH PH20803A patent/PH13858A/en unknown
- 1978-02-21 BE BE185321A patent/BE864139A/fr not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JPS618806B2 (fr) | 1986-03-18 |
IE780335L (en) | 1978-08-22 |
CH632164A5 (de) | 1982-09-30 |
SE7802014L (sv) | 1978-08-23 |
NL189281C (nl) | 1993-03-01 |
AU3334378A (en) | 1979-08-23 |
IT1092337B (it) | 1985-07-06 |
FR2380782B1 (fr) | 1980-01-18 |
AT363177B (de) | 1981-07-10 |
JPS53104719A (en) | 1978-09-12 |
AU516946B2 (en) | 1981-07-02 |
BE864139A (fr) | 1978-08-21 |
DE2807202C2 (de) | 1987-04-02 |
NL189281B (nl) | 1992-10-01 |
DE2807202A1 (de) | 1978-08-24 |
IT7819791A0 (it) | 1978-01-30 |
ZA78890B (en) | 1979-01-31 |
SE444647B (sv) | 1986-04-28 |
GB1546027A (en) | 1979-05-16 |
PH13858A (en) | 1980-10-22 |
IL54063A0 (en) | 1978-04-30 |
LU79090A1 (fr) | 1979-05-25 |
US4082737A (en) | 1978-04-04 |
ATA124578A (de) | 1980-12-15 |
NL7801422A (nl) | 1978-08-24 |
CA1099633A (fr) | 1981-04-21 |
NZ186489A (en) | 1981-01-23 |
DK78378A (da) | 1978-08-23 |
IE46409B1 (en) | 1983-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2380782A1 (fr) | Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer | |
ATE271863T1 (de) | Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren | |
ES2113346T3 (es) | Metodo para potenciar el transporte de moleculas exogenas a traves de la membrana. | |
KR950016783A (ko) | 조절 방출용 약학 조성물 | |
SE8300623D0 (sv) | Farmaceutisk komposition innehallande stabil mikrokristallin cis-platina(ii)-diammindiklorid (cisplatin) | |
GR3000534T3 (en) | Aqueous alcaline injectable solution of torasemid ready for use and process for preparation thereof | |
EA199600024A2 (ru) | Жидкая стабильная фармацевтическая композиция, содержащая уратоксидазу и лиофилизат для ее получения | |
NO870560L (no) | Nytt farmasoeytisk preparat. | |
EP0173664A3 (fr) | Dérivés de benzimidazole biologiquement actifs et leur procédé de préparation | |
HU907653D0 (en) | Process for the preparation of a medical product with cyclosporine content for oral use | |
EA000211B1 (ru) | Фармацевтические композиции для парентерального применения, содержащие индолкарбоновые кислоты | |
GB1514049A (en) | Cross-linked orgotein | |
TR199800716T2 (xx) | Trombosit k�melenme inhibit�rleri ihtiva eden farmas�tik terkipler. | |
US4822782A (en) | Method for treating AIDS using streptovaricin C compounds | |
KR910015297A (ko) | 오메프라졸 경구용 약제와 그 제조방법 | |
JPS6045532A (ja) | 血糖降下剤 | |
SE8106498L (sv) | Kvaternera salter av n,n3-di(beta-brompropionyl)-n1,n2-dispirotripiperazinium, forfarande for framstellning av desamma och lekemedelspreparat innehallande desamma | |
KR950000149A (ko) | 오메프라졸 주사용 제제 | |
KR880003623A (ko) | 시알로실글리세로리피드로 된 신경장해질환 치료제 | |
KR820000291B1 (ko) | 불용성 약제의 가용화 방법 | |
JPS6045527A (ja) | 血圧降下剤 | |
KR960041363A (ko) | 우레이트 옥시디아제를 함유하는 안정한 액체 조성물 및 그의 제조를 위한 동결건조조성물 | |
KR890001528A (ko) | 성인 t-세포 백혈병/임파종의 억제를 위한 아바론, 아바롤 및 그 유도체의 용도 | |
KR900000081A (ko) | 트리암테렌의 약학적 액제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TP | Transmission of property | ||
ST | Notification of lapse |